IRIDEX Corporation recently released long-term glaucoma efficacy data for patients treated with its MicroPulse® P3 (MP3) device, and was also recently honored by Frost & Sullivan as a recipient of its 2016 Growth, Innovation & Leadership Awards.
The MP3 device data was originally presented at the European Glaucoma Society (EGS) meeting this past June in Prague. The data was reportedly the results of retrospective case studies that aimed to evaluate and present the long-term efficacy of MicroPulse transscleral cyclophotocoagulation (MPCPC) in subjects with refractory glaucoma treated from a prior prospective trial concluded in 2014. The follow-up data highlighted six and-a-half year of efficacy data in patients with refractory glaucoma, and the presenters reported the data shows the MicroPulse is safe and efficacious for the acute reduction of intraocular pressure (IOP).
Click here to read the full press release.
And earlier this week, IRIDEX was honored by Frost & Sullivan at a gala ceremony for its 2016 Growth, Innovation & Leadership Awards. The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future. IRIDEX was presented with the 2016 European Glaucoma Devices New Product Innovation Award.
Click here to read the full press release.
Source: IRIDEX Corporation